Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $335.1 million.

  • Ligand Pharmaceuticals' Goodwill & Intangibles fell 1185.81% to $335.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.1 million, marking a year-over-year decrease of 1185.81%. This contributed to the annual value of $371.9 million for FY2024, which is 771.21% down from last year.
  • Ligand Pharmaceuticals' Goodwill & Intangibles amounted to $335.1 million in Q3 2025, which was down 1185.81% from $351.7 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Goodwill & Intangibles registered a high of $774.3 million during Q1 2021, and its lowest value of $318.6 million during Q3 2023.
  • For the 5-year period, Ligand Pharmaceuticals' Goodwill & Intangibles averaged around $476.7 million, with its median value being $396.7 million (2024).
  • Data for Ligand Pharmaceuticals' Goodwill & Intangibles shows a peak YoY increase of 15736.14% (in 2021) and a maximum YoY decrease of 5201.34% (in 2021) over the last 5 years.
  • Over the past 5 years, Ligand Pharmaceuticals' Goodwill & Intangibles (Quarter) stood at $376.7 million in 2021, then fell by 9.09% to $342.5 million in 2022, then rose by 17.67% to $403.0 million in 2023, then dropped by 7.71% to $371.9 million in 2024, then dropped by 9.9% to $335.1 million in 2025.
  • Its Goodwill & Intangibles stands at $335.1 million for Q3 2025, versus $351.7 million for Q2 2025 and $359.9 million for Q1 2025.